Payment overview · 2025
General Payments
$1,118.71
51 reported records · 14 companies
Healthcare provider profile · identity verified
John Perry Davis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHARLESTON, SC · NPI 1588608483
Verified facts
What the public records show
CMS Open Payments records show John Perry Davis, MD received $1,118.71 in general payments during 2025 across 51 reported records.
PFIZER INC. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $252.86 | 22.6% | 15 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $223.66 | 20.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $144.10 | 12.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.96 | 8.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.44 | 6.8% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $74.72 | 6.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.36 | 6.0% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $40.54 | 3.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.56 | 3.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.26 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.35 | 2.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.82 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.38 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.70 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,118.71 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $154.48 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $154.48 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $138.10 | 7 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $114.76 | 8 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $114.76 | 8 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $114.76 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $100.37 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.10 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.10 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $76.44 | 4 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $74.72 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $69.18 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.34 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.34 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.00 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $44.59 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $44.59 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $42.39 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $40.54 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.73 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.62 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 180 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 123 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
123 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
180 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 446 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 395 | 121 |
| Losartan Potassium | Losartan Potassium | 320 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 292 | 86 |
| Omeprazole | Omeprazole | 286 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 85 |
| Gabapentin | Gabapentin | 218 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 67 |
| Eliquis | Apixaban | 180 | 40 |
| Metformin Hcl | Metformin Hcl | 179 | 53 |
| Metformin Hcl Er | Metformin Hcl | 177 | 57 |
| Lisinopril | Lisinopril | 165 | 50 |
| Simvastatin | Simvastatin | 141 | 37 |
| Meloxicam | Meloxicam | 134 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 49 |
| Mounjaro | Tirzepatide | 123 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 25 |
| Valsartan | Valsartan | 115 | 36 |
| Atenolol | Atenolol | 112 | 32 |
| Famotidine | Famotidine | 108 | 35 |
| Lorazepam | Lorazepam | 104 | 29 |
| Mirtazapine | Mirtazapine | 97 | 28 |
| Ozempic | Semaglutide | 93 | 15 |
| Benazepril Hcl | Benazepril Hcl | 90 | 26 |
| Montelukast Sodium | Montelukast Sodium | 87 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 85 | 21 |
| Furosemide | Furosemide | 84 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 82 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 25 |
| Trazodone Hcl | Trazodone Hcl | 81 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 19 |
| Sertraline Hcl | Sertraline Hcl | 77 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 30 |
| Spironolactone | Spironolactone | 73 | 20 |
| Synthroid | Levothyroxine Sodium | 73 | 19 |
| Potassium Chloride | Potassium Chloride | 69 | 24 |
| Clonazepam | Clonazepam | 65 | 16 |
| Donepezil Hcl | Donepezil Hcl | 65 | 24 |
| Xarelto | Rivaroxaban | 65 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 16 |
| Prednisone | Prednisone | 58 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 22 |
| Memantine Hcl | Memantine Hcl | 56 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 15 |
| Trulicity | Dulaglutide | 54 | 12 |
| Allopurinol | Allopurinol | 53 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 19 |
| Alprazolam | Alprazolam | 52 | 11 |
| Carvedilol | Carvedilol | 52 | 16 |
| Propranolol Hcl | Propranolol Hcl | 52 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 18 |
| Ezetimibe | Ezetimibe | 47 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 13 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 12 |
| Celecoxib | Celecoxib | 34 | 13 |
| Januvia | Sitagliptin Phosphate | 34 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | 12 |
| Meclizine Hcl | Meclizine Hcl | 30 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 19 |
| Pitavastatin Calcium | Pitavastatin Calcium | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Colchicine | Colchicine | 18 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 12 |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Temazepam | Temazepam | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Singulair | Montelukast Sodium | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,118.71 · 51 records | PFIZER INC. | ABRYSVO, ACCRUFER, AREXVY, Ambulatory Monitoring & Diagnostics Undivided, COMIRNATY, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, KRYSTEXXA, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, WaveWriter Alpha Prime 16, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error